Cann reiterated their hold rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a report released on Monday morning.

“Acceleron announced today preliminary results from the first two cohorts in Part 1 of the phase II clinical study of ACE-083 in patients with facioscapulohumeral dystrophy (FSHD). Results from the tibialis anterior cohort demonstrated patients treated with ACE-083 generated a mean total muscle volume increase of 12.6%; this was associated with a mean improvement in muscle fat fraction of 5.3%. Results from the biceps brachii cohort of the studyl demonstrated patients treated with ACE-083 generated a mean total muscle volume gain of 13.2%; this was associated with a mean improvement in muscle fat fraction of 0.6%.”,” Cann’s analyst commented.

A number of other research firms have also recently weighed in on XLRN. BidaskClub upgraded shares of Acceleron Pharma from a hold rating to a buy rating in a research report on Wednesday, December 27th. Oppenheimer reiterated a hold rating on shares of Acceleron Pharma in a research report on Monday. Royal Bank of Canada initiated coverage on shares of Acceleron Pharma in a research report on Thursday, September 14th. They set a sector perform rating and a $44.00 price objective on the stock. Barclays boosted their target price on shares of Acceleron Pharma from $42.00 to $50.00 and gave the company an overweight rating in a research note on Wednesday, September 20th. Finally, HC Wainwright initiated coverage on shares of Acceleron Pharma in a research note on Thursday, October 12th. They set a buy rating and a $57.00 target price for the company. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. Acceleron Pharma presently has an average rating of Buy and an average target price of $44.56.

Acceleron Pharma (XLRN) traded down $0.10 during mid-day trading on Monday, reaching $43.91. 258,500 shares of the company’s stock were exchanged, compared to its average volume of 320,788. Acceleron Pharma has a fifty-two week low of $23.07 and a fifty-two week high of $44.80. The company has a market capitalization of $1,930.00, a PE ratio of -17.02 and a beta of 1.59.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. During the same quarter in the previous year, the business posted ($0.55) earnings per share. The business’s revenue was up .0% compared to the same quarter last year. sell-side analysts expect that Acceleron Pharma will post -2.65 earnings per share for the current year.

In related news, Director Jean George sold 105,122 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the sale, the director now directly owns 1,250 shares of the company’s stock, valued at $44,662.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Matthew L. Sherman sold 4,633 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.71, for a total transaction of $197,875.43. Following the completion of the sale, the executive vice president now directly owns 77,700 shares of the company’s stock, valued at $3,318,567. The disclosure for this sale can be found here. Insiders have sold 135,021 shares of company stock valued at $5,034,598 over the last three months. Insiders own 3.90% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC lifted its stake in Acceleron Pharma by 3.9% in the second quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 355 shares during the period. Legal & General Group Plc lifted its stake in Acceleron Pharma by 9.7% in the second quarter. Legal & General Group Plc now owns 10,470 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 923 shares during the period. Principal Financial Group Inc. lifted its stake in Acceleron Pharma by 1.0% in the second quarter. Principal Financial Group Inc. now owns 104,234 shares of the biopharmaceutical company’s stock worth $3,168,000 after acquiring an additional 1,039 shares during the period. American International Group Inc. lifted its stake in Acceleron Pharma by 8.1% in the third quarter. American International Group Inc. now owns 21,487 shares of the biopharmaceutical company’s stock worth $802,000 after acquiring an additional 1,607 shares during the period. Finally, Nationwide Fund Advisors lifted its stake in Acceleron Pharma by 8.8% in the second quarter. Nationwide Fund Advisors now owns 24,737 shares of the biopharmaceutical company’s stock worth $752,000 after acquiring an additional 2,000 shares during the period. 85.70% of the stock is owned by institutional investors.

WARNING: “Acceleron Pharma (XLRN) Given Hold Rating at Cann” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/acceleron-pharma-xlrn-given-hold-rating-at-cann/1804475.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.